Gupta, N
Creating end-to-end health programs for GLP-1 users: GLP-1 therapy creates needs beyond medication, prompting demand for integrated health frameworks
Currently available GLP-1 receptor agonists in the United States include exenatide (Byetta, Bydureon BCise), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound), though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
These require specialist assessment and may need dose adjustment
Of these eighty-four metabolites, two acyl-carnitines and eleven lysophospholipids were present at lower concentrations, and twenty-three phospholipids and glycerophosphoric acid (the substrate of diglyceride) were present at higher concentrations in the MD/d-carnitine group than the MD/l-carnitine group
Package Includes 5 sealed sterile vials (5 ml each) suitable for professional or home use